These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22362460)

  • 1. Agency is under fire for refusing to supply details of sudden deaths after first dose of multiple sclerosis drug.
    Wise J
    BMJ; 2012 Feb; 344():e1360. PubMed ID: 22362460
    [No Abstract]   [Full Text] [Related]  

  • 2. Fingolimod: cardiovascular deaths.
    Prescrire Int; 2012 Apr; 21(126):99. PubMed ID: 22515137
    [No Abstract]   [Full Text] [Related]  

  • 3. Fingolimod for multiple sclerosis.
    Pelletier D; Hafler DA
    N Engl J Med; 2012 Jan; 366(4):339-47. PubMed ID: 22276823
    [No Abstract]   [Full Text] [Related]  

  • 4. [New disease-modifying and symptomatic therapies for multiple sclerosis].
    Weise G; Buttmann M
    MMW Fortschr Med; 2012 Apr; 154(7):64-6. PubMed ID: 22558878
    [No Abstract]   [Full Text] [Related]  

  • 5. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].
    Komoly S
    Ideggyogy Sz; 2012 Nov; 65(11-12):421-2. PubMed ID: 23289178
    [No Abstract]   [Full Text] [Related]  

  • 6. Gilenya safety update: cardiac and macula.
    Huggins A; Sergott RC
    Curr Opin Ophthalmol; 2012 Nov; 23(6):457-9. PubMed ID: 23047163
    [No Abstract]   [Full Text] [Related]  

  • 7. New drugs may improve, complicate treatment for multiple sclerosis.
    Link H; Martin R
    Nat Med; 2010 Mar; 16(3):272. PubMed ID: 20208513
    [No Abstract]   [Full Text] [Related]  

  • 8. [A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)].
    Popova NF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):110-3. PubMed ID: 21916166
    [No Abstract]   [Full Text] [Related]  

  • 9. Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis.
    Castillo-Trivino T; Lopetegui I; Alarcón-Duque JA; López de Munain A; Olascoaga J
    J Neurol Neurosurg Psychiatry; 2015 Aug; 86(8):931-2. PubMed ID: 25835036
    [No Abstract]   [Full Text] [Related]  

  • 10. Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod.
    Tully T; Barkley A; Silber E
    Neurology; 2015 May; 84(19):1999-2001. PubMed ID: 25878178
    [No Abstract]   [Full Text] [Related]  

  • 11. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
    Massberg S; von Andrian UH
    N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
    Castrop F; Kowarik MC; Albrecht H; Krause M; Haslinger B; Zimmer C; Berthele A; Hemmer B
    Neurology; 2012 Mar; 78(12):928-30. PubMed ID: 22402856
    [No Abstract]   [Full Text] [Related]  

  • 13. [Multiple sclerosis and pregnancy].
    Ruuskanen J; Malm H; Airas L
    Duodecim; 2013; 129(14):1457-64. PubMed ID: 23961604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report.
    Conzett KB; Kolm I; Jelcic I; Kamarachev J; Dummer R; Braun R; French LE; Linnebank M; Hofbauer GF
    Arch Dermatol; 2011 Aug; 147(8):991-2. PubMed ID: 21844470
    [No Abstract]   [Full Text] [Related]  

  • 15. Infections cast cloud over Novartis' MS therapy.
    Garber K
    Nat Biotechnol; 2008 Aug; 26(8):844-5. PubMed ID: 18688218
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral therapy for multiple sclerosis--sea change or incremental step?
    Carroll WM
    N Engl J Med; 2010 Feb; 362(5):456-8. PubMed ID: 20089958
    [No Abstract]   [Full Text] [Related]  

  • 17. Trial watch: Phase III promise for oral multiple sclerosis therapy.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180099
    [No Abstract]   [Full Text] [Related]  

  • 18. [Emerging treatments for multiple sclerosis].
    Nau JY
    Rev Med Suisse; 2010 Jun; 6(251):1162-3. PubMed ID: 20572362
    [No Abstract]   [Full Text] [Related]  

  • 19. Multiple sclerosis poses tough drug development challenges.
    Senior K
    Drug Discov Today; 2005 Dec; 10(23-24):1583-4. PubMed ID: 16376813
    [No Abstract]   [Full Text] [Related]  

  • 20. Oral fingolimod (gilenya) for multiple sclerosis.
    Med Lett Drugs Ther; 2010 Dec; 52(1353-1354):98-9. PubMed ID: 21344782
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.